1-3 of 3
Keywords: Anti-tumor necrosis factor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study

Available to Purchase
Subject Area:
Topic Article Package: Moksha , Gastroenterology
Brigida Barberio, Fabiana Zingone, Leonardo Frazzoni, Renata D’Incà, Maria Chiara Maccarone, Matteo Ghisa, Davide Massimi, Greta Lorenzon, Edoardo Vincenzo Savarino
Journal: Digestive Diseases
Dig Dis (2021) 39 (1): 16–24.
https://doi.org/10.1159/000508865
Published Online: 25 May 2020
...Brigida Barberio; Fabiana Zingone; Leonardo Frazzoni; Renata D’Incà; Maria Chiara Maccarone; Matteo Ghisa; Davide Massimi; Greta Lorenzon; Edoardo Vincenzo Savarino Background: Head-to-head comparison studies evaluating the effectiveness and tolerability of anti-tumor necrosis factor (anti-TNF...
View article titled, Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study
Open the PDF for Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study in another window
Journal Articles

Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey

Available to Purchase
Subject Area:
Gastroenterology
Stephan R. Vavricka, Milos Spasojevic, Gerhard Rogler, Alain M. Schoepfer, Frank Seibold, Jan Borovicka, Pascal Frei, Jonas Zeitz, Thomas Greuter, Christine Manser, Michael Scharl, Benjamin Misselwitz, Alex Straumann, Pierre Michetti, Luc Biedermann, for the Swiss IBDnet
Journal: Digestive Diseases
Dig Dis (2017) 35 (5): 423–432.
https://doi.org/10.1159/000475494
Published Online: 09 June 2017
..., patients receiving CZP were prospectively included all over Switzerland in (non-) academic hospitals and private practice. Results: We included 104 CD patients (52 male; only 22.1% anti-tumor necrosis factor (TNF) naïve, CZP as third anti-TNF agent in 46.2%) with follow-up time between 6 weeks up to 5...
View article titled, Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
Open the PDF for Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey in another window
Journal Articles

Have Biologics Changed the Natural History of Crohn's Disease?

Available to Purchase
Subject Area:
Gastroenterology
Michael D. Mandel, Pal Miheller, Katalin Müllner, Petra A. Golovics, Peter L. Lakatos
Journal: Digestive Diseases
Dig Dis (2014) 32 (4): 351–359.
https://doi.org/10.1159/000358135
Published Online: 23 June 2014
...Michael D. Mandel; Pal Miheller; Katalin Müllner; Petra A. Golovics; Peter L. Lakatos Crohn's disease (CD) is a progressive condition, with most patients developing a penetrating or stricturing phenotype over time. The introduction of anti-tumor necrosis factor (TNF) therapies over the past 10-15...
View article titled, Have Biologics Changed the Natural History of Crohn's Disease?
Open the PDF for Have Biologics Changed the Natural History of Crohn's Disease? in another window